Search

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

Frost & Sullivan puts some flesh on the bones of the idea that nanotechnology can be a profitable tool in drug development.

With global revenues of $110 billion last year, and an aging population, the nascent "neurotechnology" market appears poised for huge growth.

The UK government has created two new Enterprise Capital Funds (ECF) under its £40 million scheme to aid high tech businesses caught in the equity gap.

Open source software has broken the stranglehold of proprietary software vendors. Could the Biological Open Source initiative do the same in biotech?

Researchers from Helsinki University have found a way to fight cancer by chewing gum. The gum contains a substance which breaks down carcinogens in the mouth caused by smoking and drinking.

Secure Access Solutions, a spin-off from the University of Warwick, has developed a new kind of magnifying lens to help the visually impaired type their pin codes into card readers in shops. It is seeking licensees and investors.

EU technology policy is moving beyond the numbers game, and getting down to economic basics.

The European Commission wants businesses to spend more on research and development - and to help encourage that, the agency is preparing a volley of government proposals for the Autumn.

The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.

Researchers at four European universities are collaborating to develop software that will help encourage the take-up of so called pervasive computing.

European biotech is a hot topic among investors. They have supported as many start-ups as in the US but have seen far from equivalent returns. So what's going on? Science|Business talks to biotechnology consultant John Hodgson.

Last week's Innovate2006 conference in Zaragoza included a pre-conference tour of the region with an interesting visit of Endesa and one of the largest Spanish windmill farms, located just a few miles north off Zaragoza.

Nanomedicine can be more than a case of adding a trendy label to traditional approaches to pharmaceuticals.

Yet another consultation is under way into the safety of nanotechnology. This time you have an opportunity to give your views on "the use of nanotechnologies in relation to food".

Intellectual property battles are not always settled in the marketplace. Epic, life-and-death struggles often take place in the judicial arena.

Free public access to Europe’s leading biological databases will be guaranteed under a €16.7 million EU project launched this month.

CERN, the European Laboratory for Particle Phyics, has launched the second phase of Openlab, its partnership with IT companies for the development of advanced computing facilities.

The European Union was trumped last week when France announced plans to boost the country's biofuel use to 10 per cent by 2015.